ArticlePloS one2025
CanRisk-GP protocol: A feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care.British journal of cancer · 2026Article
- Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment.British journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanRisk is a risk assessment tool that implements the BOADICEA multifactorial breast cancer risk model. The BOADICEA model is recommended for use by the National Institute for Health and Care Excellence (NICE) in English, Welsh, and Northern Irish secondary/tertiary care to identify women who may be at moderate or high risk of developing breast cancer. BOADICEA combines information on cancer family history, demographic, lifestyle, hormonal risk factors and mammographic density with polygenic scores (PGS). Offering risk assessment using CanRisk in general practice has the potential to identify more women at moderate or high risk of developing breast cancer and improve their management and the appropriateness of referrals to secondary/tertiary care. MATERIALS AND
methodsIn this feasibility study we plan to invite women aged 40-49 years from 5-8 practices across Cambridgeshire and Peterborough in England, UK to complete a breast cancer risk assessment using CanRisk via a newly developed public-facing version of the CanRisk tool and provide saliva samples for PGS. The study team will provide a risk report back to both the participants and their GP, with those women at above-population level risk advised to make an appointment with their GP to be referred to the clinical genetics service and subsequently managed in line with current NICE guidelines. This study will provide evidence on (1) whether offering cancer risk assessment including PGS in general practice is feasible and acceptable to women and healthcare professionals; (2) whether this approach can identify women at above-population level risk of breast cancer who would otherwise not have been identified and so not had access to risk-reducing options; and (3) the costs associated with implementing proactive multifactorial breast cancer risk assessment in women under 50 within general practice. STUDY REGISTRATION NUMBER: This study is listed on the ISRCTN registry. The registration number is ISRCTN17376192.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.